Sugi Predict

Sugi Predict / Compounds / SCHEMBL19810194

SCHEMBL19810194

SCHEMBL19810194

COc1ccc(-c2cn3c(=O)c(Cc4ccco4)nc-3c(Cc3ccccc3)[nH]2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.39
▸ HSD17B10 Q99714 7/20 0.39
▸ KDM4E B2RXH2 6/20 0.39
▸ USP2 O75604 4/20 0.39
▸ CASP1 P29466 3/20 0.39
▸ CASP7 P55210 3/20 0.39
▸ HTT P42858 3/20 0.39
▸ TSHR P16473 3/20 0.39
▸ POLB P06746 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ RECQL P46063 2/20 0.39
▸ PTPN7 P35236 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ HPGD P15428 5/20 0.38
▸ ADORA3 P0DMS8 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10012889 0.92 KDM4E (0.43) ALDH1A1HSD17B10KDM4EUSP2HTT
SCHEMBL30800221 0.91 CYP1A2 (0.43) ALDH1A1HSD17B10KDM4EUSP2CASP1
SCHEMBL19810295 0.91 CYP1A2 (0.43) ALDH1A1HSD17B10KDM4EUSP2CASP1
SCHEMBL19810310 0.91 ADORA2B (0.38) ALDH1A1HSD17B10KDM4EUSP2CASP1
SCHEMBL2670126 0.91 ALDH1A1 (0.39) ALDH1A1HSD17B10KDM4EUSP2CASP1
SCHEMBL12735455 0.91 ALDH1A1 (0.43) ALDH1A1HSD17B10KDM4EUSP2HTT
SCHEMBL4547065 0.89 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4EUSP2HTT
SCHEMBL19810212 0.88 ALDH1A1 (0.38) ALDH1A1HSD17B10KDM4EHTTTSHR
SCHEMBL28888591 0.88 PSD (0.38) ALDH1A1HSD17B10KDM4EUSP2CASP1
SCHEMBL19810320 0.88 LTB4R (0.36) ALDH1A1HSD17B10USP2CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10669280-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2020-06-02 — — US claimed
EP-3490991-A1 COELENTERAZINE ANALOGUES Promega Corporation (US) 2019-06-05 — — EP claimed
US-10000500-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2018-06-19 — — US claimed
WO-2018022865-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-02-01 — — WO claimed
US-20180030059-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 — — US claimed
CN-111116594-B C-6 modified NanoLuc analogue and preparation method and application thereof 山东大学 2021-05-28 — — CN disclosed
EP-3490991-B1 COELENTERAZINE ANALOGUES PROMEGA CORP (US) 2021-01-06 — — EP disclosed
EP-3490991-B1 COELENTERAZINE ANALOGUES PROMEGA CORP (US) 2021-01-06 — — EP disclosed
US-10669280-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2020-06-02 — — US disclosed
US-10669280-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2020-06-02 — — US disclosed
CN-111116594-A C-6 modified NanoLuc analogue and preparation method and application thereof 山东大学 2020-05-08 — — CN disclosed
US-10428075-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2019-10-01 — — US disclosed
US-20180334463-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-11-22 — — US disclosed
US-10000500-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2018-06-19 — — US disclosed
US-10000500-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2018-06-19 — — US disclosed
US-10000500-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2018-06-19 — — US disclosed
WO-2018022865-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-02-01 — — WO disclosed
US-20180030059-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 — — US disclosed
US-20180030059-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 — — US disclosed
US-20180030059-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000500-B2 Coelenterazine analogues GLB1, TCF7L2, SI ALDH1A1 3416/4885HSD17B10 2622/4885KDM4E 3097/4885
US-10669280-B2 Coelenterazine analogues GLB1, SI, TCF7L2 ALDH1A1 3541/4885HSD17B10 2616/4885KDM4E 3302/4885
US-10428075-B2 Coelenterazine analogues GLB1, SI, TCF7L2 ALDH1A1 3541/4885HSD17B10 2616/4885KDM4E 3302/4885
US-20180030059-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 ALDH1A1 3541/4885HSD17B10 2616/4885KDM4E 3302/4885
US-20180334463-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 ALDH1A1 3541/4885HSD17B10 2616/4885KDM4E 3302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback